10 Best Agritech for February 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The agritech sector presents compelling opportunities for value-focused analysis amid fluctuating commodity prices and global food demand pressures. These 10 agritech stock picks were selected using ValueSense's proprietary methodology, emphasizing intrinsic value calculations, quality ratings, and key financial metrics like ROIC, FCF margins, and debt levels. Stocks were curated from the agritech watchlist, prioritizing those trading below estimated intrinsic values with solid revenue bases and growth potential. This educational analysis highlights undervalued names across fertilizers, potash, equipment, and biotech crop solutions, offering a diversified stock watchlist for retail investors exploring best value stocks in commodities and ag innovation.
Featured Stock Analysis
Stock #1: Nutrien Ltd. (NTR)
| Metric | Value |
|---|---|
| Market Cap | $34.2B |
| Quality Rating | 6.4 |
| Intrinsic Value | $52.9 |
| 1Y Return | 41.1% |
| Revenue | $26.3B |
| Free Cash Flow | $2,186.2M |
| Revenue Growth | (1.3%) |
| FCF margin | 8.3% |
| Gross margin | 30.4% |
| ROIC | 6.5% |
| Total Debt to Equity | 56.4% |
Investment Thesis
Nutrien Ltd. (NTR) stands out as a large-cap leader in the agritech space with a market cap of $34.2B and a Quality rating of 6.4. Its intrinsic value of $52.9 suggests potential undervaluation, supported by strong 1Y return of 41.1% and robust revenue of $26.3B. Despite a slight revenue growth dip to 1.3%, the company maintains healthy free cash flow of $2,186.2M, an FCF margin of 8.3%, gross margin of 30.4%, and ROIC of 6.5%. With total debt to equity at 56.4%, NTR demonstrates balanced financial health suitable for value analysis in the fertilizer sector.
This profile positions NTR as a stable anchor for portfolios seeking exposure to essential agricultural inputs, where steady cash generation offsets modest growth headwinds.
Key Catalysts
- Exceptional 41.1% 1Y return highlighting momentum in commodities.
- Massive $26.3B revenue base providing scale advantages.
- Solid 8.3% FCF margin and $2,186.2M cash flow for reinvestment.
- 6.5% ROIC indicating efficient capital use.
Risk Factors
- Negative revenue growth of 1.3% amid market volatility.
- Elevated 56.4% debt to equity requiring monitoring.
Stock #2: CF Industries Holdings, Inc. (CF)
| Metric | Value |
|---|---|
| Market Cap | $15.4B |
| Quality Rating | 7.3 |
| Intrinsic Value | $133.5 |
| 1Y Return | 16.7% |
| Revenue | $6,736.0M |
| Free Cash Flow | $1,712.0M |
| Revenue Growth | 12.6% |
| FCF margin | 25.4% |
| Gross margin | 39.8% |
| ROIC | 13.1% |
| Total Debt to Equity | 44.1% |
Investment Thesis
CF Industries Holdings, Inc. (CF) offers a compelling mid-cap profile with $15.4B market cap and top-tier Quality rating of 7.3. The intrinsic value at $133.5 points to significant upside, backed by 16.7% 1Y return, $6,736.0M revenue, and impressive $1,712.0M free cash flow. Positive revenue growth of 12.6%, 25.4% FCF margin, 39.8% gross margin, and 13.1% ROIC underscore operational strength, while total debt to equity of 44.1% remains manageable. This makes CF a standout in fertilizer production for undervalued stocks analysis.
The combination of high margins and growth positions CF for sustained performance in rising agricultural demand cycles.
Key Catalysts
- High 7.3 Quality rating and 13.1% ROIC for superior efficiency.
- Strong 12.6% revenue growth driving expansion.
- Exceptional 25.4% FCF margin with $1,712.0M cash generation.
- Attractive intrinsic value of $133.5 for value seekers.
Risk Factors
- Moderate 16.7% 1Y return trails top performers.
- 44.1% debt levels in cyclical industry.
Stock #3: NOV Inc. (NOV)
| Metric | Value |
|---|---|
| Market Cap | $6,825.0M |
| Quality Rating | 6.1 |
| Intrinsic Value | $25.4 |
| 1Y Return | 18.8% |
| Revenue | $8,744.0M |
| Free Cash Flow | $876.0M |
| Revenue Growth | (1.4%) |
| FCF margin | 10.0% |
| Gross margin | 20.2% |
| ROIC | 5.6% |
| Total Debt to Equity | 45.3% |
Investment Thesis
NOV Inc. (NOV), with a $6,825.0M market cap and Quality rating of 6.1, provides equipment solutions for agritech-adjacent energy-ag sectors. Intrinsic value of $25.4 indicates undervaluation, complemented by 18.8% 1Y return, $8,744.0M revenue, and $876.0M free cash flow. Metrics include 1.4% revenue growth, 10.0% FCF margin, 20.2% gross margin, 5.6% ROIC, and 45.3% total debt to equity. NOV's scale in revenue supports its role in agritech stock picks.
Despite growth challenges, cash flow stability aids resilience in volatile markets.
Key Catalysts
- Solid 18.8% 1Y return showing recovery.
- Large $8,744.0M revenue for operational leverage.
- 10.0% FCF margin supporting dividends or buybacks.
- Intrinsic value upside at $25.4.
Risk Factors
- Revenue contraction of 1.4%.
- 45.3% debt to equity in capital-intensive ops.
Stock #4: FMC Corporation (FMC)
| Metric | Value |
|---|---|
| Market Cap | $1,885.5M |
| Quality Rating | 4.3 |
| Intrinsic Value | $50.0 |
| 1Y Return | -60.4% |
| Revenue | $3,467.4M |
| Free Cash Flow | $88.5M |
| Revenue Growth | (18.3%) |
| FCF margin | 2.6% |
| Gross margin | 37.0% |
| ROIC | (32.7%) |
| Total Debt to Equity | 13.5% |
Investment Thesis
FMC Corporation (FMC) features a $1,885.5M market cap and Quality rating of 4.3, with intrinsic value at $50.0 signaling rebound potential despite -60.4% 1Y return. Key stats: $3,467.4M revenue, $88.5M free cash flow, 18.3% revenue growth, 2.6% FCF margin, 37.0% gross margin, 32.7% ROIC, and low 13.5% total debt to equity. This positions FMC for analysis in crop protection amid sector pressures.
Low debt offers flexibility for turnaround efforts.
Key Catalysts
- Strong 37.0% gross margin preserving profitability.
- Intrinsic value of $50.0 vs. recent declines.
- Reduced 13.5% debt for balance sheet strength.
Risk Factors
- Sharp -60.4% 1Y return and negative ROIC.
- Significant 18.3% revenue drop.
- Low 2.6% FCF margin.
Stock #5: Intrepid Potash, Inc. (IPI)
| Metric | Value |
|---|---|
| Market Cap | $423.8M |
| Quality Rating | 6.1 |
| Intrinsic Value | $36.4 |
| 1Y Return | 28.1% |
| Revenue | $278.3M |
| Free Cash Flow | $46.2M |
| Revenue Growth | 8.9% |
| FCF margin | 16.6% |
| Gross margin | 16.8% |
| ROIC | (43.6%) |
| Total Debt to Equity | 1.5% |
Investment Thesis
Intrepid Potash, Inc. (IPI) has a $423.8M market cap, Quality rating 6.1, and intrinsic value $36.4. It delivered 28.1% 1Y return, $278.3M revenue, $46.2M free cash flow, 8.9% revenue growth, 16.6% FCF margin, 16.8% gross margin, 43.6% ROIC, and minimal 1.5% total debt to equity. IPI appeals for potash-focused value stocks.
Positive growth and low debt mitigate efficiency issues.
Key Catalysts
- Robust 28.1% 1Y return.
- 8.9% revenue growth trajectory.
- High 16.6% FCF margin.
- Near-zero 1.5% debt burden.
Risk Factors
- Negative 43.6% ROIC.
- Modest gross margin at 16.8%.
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #6: American Vanguard Corporation (AVD)
| Metric | Value |
|---|---|
| Market Cap | $143.7M |
| Quality Rating | 4.7 |
| Intrinsic Value | $19.8 |
| 1Y Return | -5.1% |
| Revenue | $530.1M |
| Free Cash Flow | $2,989.0K |
| Revenue Growth | (4.3%) |
| FCF margin | 0.6% |
| Gross margin | 24.1% |
| ROIC | (17.1%) |
| Total Debt to Equity | 90.8% |
Investment Thesis
American Vanguard Corporation (AVD), $143.7M market cap, Quality 4.7, intrinsic value $19.8. Metrics show -5.1% 1Y return, $530.1M revenue, $2,989.0K free cash flow, 4.3% revenue growth, 0.6% FCF margin, 24.1% gross margin, 17.1% ROIC, 90.8% total debt to equity. AVD warrants scrutiny in specialty chemicals for ag.
Revenue scale contrasts with margin pressures.
Key Catalysts
- $530.1M revenue providing foundation.
- Intrinsic value potential at $19.8.
- 24.1% gross margin resilience.
Risk Factors
- High 90.8% debt exposure.
- Weak 0.6% FCF margin and negative ROIC.
- 4.3% revenue decline.
Stock #7: Cibus, Inc. (CBUS)
| Metric | Value |
|---|---|
| Market Cap | $104.0M |
| Quality Rating | 4.6 |
| Intrinsic Value | $3.8 |
| 1Y Return | -21.3% |
| Revenue | $3,794.0K |
| Free Cash Flow | ($51.7M) |
| Revenue Growth | (8.6%) |
| FCF margin | (1,363.0%) |
| Gross margin | 83.8% |
| ROIC | (31.1%) |
| Total Debt to Equity | 65.3% |
Investment Thesis
Cibus, Inc. (CBUS) boasts $104.0M market cap, Quality 4.6, intrinsic value $3.8. Despite -21.3% 1Y return, it has $3,794.0K revenue, $51.7M free cash flow, 8.6% revenue growth, 1,363.0% FCF margin, 83.8% gross margin, 31.1% ROIC, 65.3% total debt to equity. High gross margins highlight biotech promise in seed tech.
Early-stage dynamics explain cash burn.
Key Catalysts
- Exceptional 83.8% gross margin.
- Intrinsic value at $3.8 for speculators.
Risk Factors
- Severe negative FCF and margins.
- 8.6% revenue contraction.
- High 65.3% debt and negative ROIC.
Stock #8: Codexis, Inc. (CDXS)
| Metric | Value |
|---|---|
| Market Cap | $102.4M |
| Quality Rating | 6.2 |
| Intrinsic Value | $5.7 |
| 1Y Return | -71.4% |
| Revenue | $52.9M |
| Free Cash Flow | ($61.7M) |
| Revenue Growth | (17.9%) |
| FCF margin | (116.5%) |
| Gross margin | 79.3% |
| ROIC | (106.7%) |
| Total Debt to Equity | (90.7%) |
Investment Thesis
Codexis, Inc. (CDXS), $102.4M market cap, Quality 6.2, intrinsic value $5.7. Faces -71.4% 1Y return, $52.9M revenue, $61.7M free cash flow, 17.9% revenue growth, 116.5% FCF margin, 79.3% gross margin, 106.7% ROIC, 90.7% total debt to equity. Enzyme tech for ag apps shows margin strength.
Negative equity adds complexity.
Key Catalysts
- Strong 79.3% gross margin.
- 6.2 Quality rating amid challenges.
Risk Factors
- Extreme losses in returns, FCF, ROIC.
- Revenue decline and negative debt metrics.
Stock #9: ImmuCell Corporation (ICCC)
| Metric | Value |
|---|---|
| Market Cap | $61.2M |
| Quality Rating | 6.8 |
| Intrinsic Value | $1,724.5 |
| 1Y Return | 31.1% |
| Revenue | $8,086.9M |
| Free Cash Flow | $2,691.1K |
| Revenue Growth | 34.1% |
| FCF margin | 0.0% |
| Gross margin | 41.6% |
| ROIC | 0.0% |
| Total Debt to Equity | 16.9% |
Investment Thesis
ImmuCell Corporation (ICCC), $61.2M market cap, Quality 6.8, standout intrinsic value $1,724.5. Boasts 31.1% 1Y return, $8,086.9M revenue, $2,691.1K free cash flow, 34.1% revenue growth, 0.0% FCF margin, 41.6% gross margin, 0.0% ROIC, 16.9% total debt to equity. High growth in animal health merits attention.
Massive revenue and intrinsic value suggest deep value.
Key Catalysts
- Impressive 34.1% revenue growth.
- 31.1% 1Y return and 6.8 Quality.
- Elevated intrinsic value of $1,724.5.
Risk Factors
- Zero FCF margin and ROIC.
- Modest free cash flow scale.
Stock #10: Bioceres Crop Solutions Corp. (BIOX)
| Metric | Value |
|---|---|
| Market Cap | $37.6M |
| Quality Rating | 4.7 |
| Intrinsic Value | $5.2 |
| 1Y Return | -87.4% |
| Revenue | $318.2M |
| Free Cash Flow | $12.0M |
| Revenue Growth | (27.9%) |
| FCF margin | 3.8% |
| Gross margin | 39.1% |
| ROIC | (1.4%) |
| Total Debt to Equity | 95.9% |
Investment Thesis
Bioceres Crop Solutions Corp. (BIOX), $37.6M market cap, Quality 4.7, intrinsic value $5.2. Shows -87.4% 1Y return, $318.2M revenue, $12.0M free cash flow, 27.9% revenue growth, 3.8% FCF margin, 39.1% gross margin, 1.4% ROIC, 95.9% total debt to equity. Crop solutions offer recovery potential.
Positive FCF provides a base.
Key Catalysts
- 39.1% gross margin strength.
- $12.0M free cash flow positivity.
- Intrinsic value at $5.2.
Risk Factors
- Steep -87.4% 1Y loss.
- High 95.9% debt and negative growth/ROIC.
Portfolio Diversification Insights
These 10 agritech stocks create balanced exposure across fertilizers (NTR, CF), equipment (NOV), potash (IPI), chemicals (FMC, AVD), and biotech (CBUS, CDXS, ICCC, BIOX). Large-caps like NTR $34.2B anchor stability, while small-caps like BIOX $37.6M add growth tilt. Sector allocation: 40% fertilizers/commodities, 30% crop solutions, 30% biotech/equipment. Pairing high-quality CF (7.3 rating) with low-debt IPI reduces volatility; avoid over-concentration in negative ROIC names like FMC. This mix supports portfolio diversification in undervalued agritech stocks, blending scale with innovation.
Market Timing & Entry Strategies
Consider entry during commodity price dips or post-earnings when intrinsic values exceed current levels, such as NTR below $52.9. Scale in on pullbacks for high-debt names like AVD; monitor ROIC improvements for biotech like CDXS. Use ValueSense tools for backtested strategies, targeting 6-12 month holds amid ag demand cycles. Dollar-cost average into top performers like CF during revenue growth phases.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Abrams Capital Management Portfolio in 2026: Top Holdings & Recent Changes
- Auxier Asset Management Portfolio in 2026: Top Holdings & Recent Changes
- Chase Coleman - Tiger Global Management Portfolio in 2026: Top Holdings & Recent Changes
- Brandes Investment Partners Portfolio in 2026: Top Holdings & Recent Changes
- Bill Ackman - Pershing Square Capital Management Portfolio in 2026: Top Holdings & Recent Changes
FAQ Section
How were these stocks selected?
These agritech stock picks were chosen from ValueSense's curated watchlist using intrinsic value estimates, quality ratings, and metrics like ROIC and FCF margins to identify undervalued opportunities.
What's the best stock from this list?
CF Industries (CF) leads with a 7.3 Quality rating, 13.1% ROIC, and 25.4% FCF margin, making it a top contender for balanced stock analysis.
Should I buy all these stocks or diversify?
Diversification across large-caps like NTR and small-caps like BIOX is key; allocate based on risk tolerance rather than holding all for optimal portfolio construction.
What are the biggest risks with these picks?
Common risks include revenue declines (e.g., FMC's -18.3%), high debt (AVD 90.8%), and negative ROIC in biotechs, amplified by commodity cycles.
When is the best time to invest in these stocks?
Target entries when prices dip below intrinsic values (e.g., NTR under $52.9) or during sector recoveries, using ValueSense screeners for timing signals.